GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers: London, UK Thursday, November 14, 2024, 15:00 Hrs [IST] GSK plc announced t ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

智通财经APP获悉，英国制药巨头葛兰素史克公司 (GSK.US)表示，其血液癌症药物在与另一种癌症治疗药物联合使用时，显著降低了癌症患者们死亡风险，进一步提高了将之前被FDA与欧洲药品管理局宣布撤回的抗癌药物Blenrep重新推向市场的前景。

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

The FTSE 100 drugmaker said the trial, involving 494 participants, demonstrated that Blenrep combined with bortezomib and ...

Controller medications, also known as daily maintenance medications, are a critical tool for managing asthma — reducing daily ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

Aytu BioPharma (NASDAQ: AYTU) is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...